Kush M Parmar, MD, PhD, is a Managing Partner at 5AM Ventures. He joined 5AM Ventures in 2010 from Harvard Medical School, where he was an NIH-sponsored M.D./PhD Physician Scientist Fellow in the joint Harvard-MIT Health Sciences and Technology Program. Dr. Parmar currently serves as a Director or Observer on the Boards of Arvinas, Audentes, Novira and scPharmaceuticals. He previously served as Acting VP of Strategy and Corporate Development at Novira, and as Board Observer for Envoy (acquired by Takeda), Achaogen (NASDAQ: AKAO), and Pulmatrix (NASDAQ: PULM).
Dr. Parmar serves on the Scientific Advisory Council of Princeton University’s Department of Molecular Biology and for the Grace Science Foundation. He is a Fellow of the Society of Kauffman Fellows. Before joining 5AM, Dr. Parmar completed clinical clerkships at the Massachusetts General & Brigham and Women’s Hospitals. At Princeton University, Dr. Parmar worked on developmental genetics with Nobel Prize winner Eric F. Wieschaus.
He also founded a non-profit international development organization, the Cruz Blanca Initiative. He holds an A.B. in Molecular Biology and Medieval Studies from Princeton University, a PhD in Experimental Pathology from Harvard University, and an M.D. from Harvard Medical School. Dr. Parmar is based in the Boston, MA office.
